Literature DB >> 9240697

Design of aromatic inhibitors of influenza virus neuraminidase.

M Luo1, G M Air, W J Brouillette.   

Abstract

Structure-based drug design, a terminology used to describe rational drug design by complementing the structure, spatially and chemically, of the target macromolecule, is rapidly developing as one of the innovative approaches to drug discovery. A growing volume of protein structure data and new techniques of protein structure determination make this all possible. The method of structure-based drug design and a specific example of the design of influenza virus neuraminidase is briefly presented. A whole new class of influenza virus neuraminidase inhibitors has been designed that can potentially be developed as antiinfluenza drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9240697     DOI: 10.1086/514178

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Potential New H1N1 Neuraminidase Inhibitors from Ferulic Acid and Vanillin: Molecular Modelling, Synthesis and in Vitro Assay.

Authors:  Maywan Hariono; Nurshariza Abdullah; K V Damodaran; Ezatul E Kamarulzaman; Nornisah Mohamed; Sharifah Syed Hassan; Shaharum Shamsuddin; Habibah A Wahab
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

2.  Toward development of generic inhibitors against the 3C proteases of picornaviruses.

Authors:  Kamalika Banerjee; Ruchika Bhat; V U Bhaskara Rao; Anshu Nain; Kartik Lakshmi Rallapalli; Sohona Gangopadhyay; R P Singh; Manidipa Banerjee; Bhyravabhotla Jayaram
Journal:  FEBS J       Date:  2018-12-10       Impact factor: 5.542

Review 3.  Influenza is now a preventable disease.

Authors:  J S Oxford; R Lambkin
Journal:  Int J Antimicrob Agents       Date:  2006-03-27       Impact factor: 5.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.